Background and Objectives: Limited data is available on the long-term efficacy and safety of drug-eluting stent (DES) in diffuse long lesion. Methods: From May 2006 to May 2007, a total of 335 consecutive patients (374 lesions) were underwent percutaneous coronary intervention (PCI) with implantation of long DES (��� 30mm) in real world practice. They were divided into sirolimus-eluting stent (SES, n=218) and paclitaxel-eluting stent (PES, n=117) groups and compared angiographic at 8 months and clinical outcomes for 2 years. Major adverse cardiac events (MACE) was defined as cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR). Results: Baseline characteristics between two groups were similar. Mean stent length was 44.9짹15.2 mm in SES and 47.4짹15.9 in PES. Angiographic follow-up at 8 months was performed in 47.3% and binary restenosis rate was 2.1% in SES and 5.3% in PES (p=0.094). Late loss was developed higher in SES than in PES (0.4짹0.6mm in SES vs. 0.7짹0.8mm in PES, p=0.007). Mean clinical follow-up duration was 688짹346 days. Although in-hospital MACE were not statistically different (1.8% in SES vs. 2.6% in PES, p=0.656), cumulative total MACE showed significantly higher in PES than in SES (Table 1). Conclusion: The use of DES in diffuse long coronary lesion showed acceptable low rate of clinical events. And SES is more effective and safe than PES in this real world clinical experience. Key Words: Drug-eluting stent, Long Lesion, Long-term, Outcomes